PCRX
Pacira BioSciences, Inc.Company Information
- Company Name
- Pacira BioSciences, Inc.
- CIK
- CIK0001396814
- Category
- Large accelerated filer
- Ticker: Exchange
- PCRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PCRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-16
- Last sale
- 2026-08-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 83,647
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 60,008,784
- Shares outstanding
- 39,462,000
- Ownership
- 152.07%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -6.73%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 206 | 144 | 159 | 148 | 300 | 284 | 277 | 246 | 247 | 184 | 153 | 99 | ||||||
| Short Term Investments | 45 | 58 | 80 | 99 | 145 | 210 | 208 | 208 | 157 | 142 | 125 | 136 | ||||||
| Accounts Receivable Net Current | 132 | 126 | 124 | 115 | 114 | 105 | 113 | 101 | 105 | 102 | 106 | 97 | ||||||
| Inventory Net | 135 | 150 | 153 | 158 | 148 | 134 | 125 | 112 | 103 | 97 | 104 | 97 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 67 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 30 | 37 | 33 | 43 | 37 | 28 | 22 | 24 | 20 | 19 | 22 | 19 | ||||||
| Assets Current | 615 | 515 | 548 | 563 | 746 | 760 | 745 | 690 | 632 | 543 | 510 | 447 | ||||||
| Property Plant And Equipment Net | 130 | 136 | 141 | 147 | 155 | 164 | 167 | 167 | 169 | 172 | 174 | 176 | ||||||
| Long Term Investments | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 2 | 0 | ||||||
| Operating Lease Right Of Use Asset | 45 | 39 | 42 | 44 | 47 | 49 | 49 | 54 | 56 | 59 | 61 | 63 | ||||||
| Goodwill | 20 | 20 | 20 | 20 | 20 | 22 | 0 | 0 | 163 | 163 | 163 | 163 | ||||||
| Intangible Assets Net Excluding Goodwill | 285 | 353 | 368 | 382 | 423 | 435 | 426 | 440 | 455 | 469 | 483 | 498 | ||||||
| Deferred Income Tax Assets Net | 125 | 122 | 124 | 120 | 128 | 129 | 130 | 134 | 135 | 141 | 144 | 152 | ||||||
| Assets | 1,244 | 1,209 | 1,265 | 1,298 | 1,537 | 1,587 | 1,554 | 1,522 | 1,647 | 1,583 | 1,574 | 1,534 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 18 | 14 | 15 | 18 | 30 | 23 | 19 | 19 | 19 | 9 | 16 | 17 | ||||||
| Accrued Liabilities Current | 93 | 85 | 96 | 80 | 71 | 80 | 80 | 76 | 65 | 67 | 64 | 60 | ||||||
| Operating Lease Liability Current | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | ||||||
| Convertible Debt Current | - | - | - | - | 202 | 202 | 202 | 201 | 0 | 9 | 9 | 9 | ||||||
| Secured Debt Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Debt Current | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Long Term Debt Current | - | - | 0 | - | - | - | 202 | - | - | - | - | - | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 122 | 109 | 121 | 107 | 313 | 315 | 310 | 306 | 93 | 93 | 97 | 94 | ||||||
| Convertible Debt Noncurrent | - | - | - | - | 280 | 280 | 279 | 279 | 480 | 399 | 399 | 398 | ||||||
| Secured Long Term Debt | - | - | - | - | 98 | 101 | 104 | 107 | 110 | 112 | 115 | 118 | ||||||
| Long Term Debt Noncurrent | 363 | 368 | 372 | 377 | - | - | 384 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 39 | 34 | 36 | 39 | 41 | 44 | 45 | 48 | 50 | 52 | 55 | 57 | ||||||
| Deferred Income Tax Liabilities Net | 4 | 4 | 4 | 5 | 5 | 7 | 0 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 27 | 25 | 21 | 25 | 25 | 24 | 17 | 13 | 13 | 13 | 14 | 12 | ||||||
| Liabilities | 572 | 555 | 572 | 570 | 779 | 788 | 775 | 772 | 768 | 691 | 704 | 703 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | -227 | -227 | -177 | -126 | -76 | -25 | -25 | -25 | -25 | - | 0 | - | ||||||
| Additional Paid In Capital | 1,087 | 1,074 | 1,065 | 1,050 | 1,036 | 1,024 | 1,009 | 996 | 983 | 990 | 977 | 963 | ||||||
| Retained Earnings Accumulated Deficit | -192 | -196 | -199 | -201 | -206 | -202 | -206 | -222 | -79 | -98 | -107 | -132 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 3 | 3 | 4 | 4 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | -0 | ||||||
| Stockholders Equity | 672 | 654 | 693 | 727 | 758 | 799 | 778 | 750 | 879 | 892 | 870 | 832 | ||||||
| Liabilities And Stockholders Equity | 1,244 | 1,209 | 1,265 | 1,298 | 1,537 | 1,587 | 1,554 | 1,522 | 1,647 | 1,583 | 1,574 | 1,534 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 49 | 48 | 48 | 48 | 48 | 47 | 47 | 47 | 47 | 47 | 46 | 46 | ||||||
| Shares Outstanding | 40 | 39 | 41 | 43 | 45 | 46 | 46 | 46 | 46 | 47 | 46 | 46 | ||||||
| Treasury Stock Common Shares | 9 | 9 | 7 | 5 | 3 | 1 | 1 | 1 | 1 | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPacira BioSciences, Inc. (PCRX) — SEC Financial Statements & Analysis
Pacira BioSciences, Inc. (PCRX) is a pharmaceutical preparations company, incorporated in DE. Pacira BioSciences, Inc. trades on Nasdaq as: PCRX. Pacira BioSciences, Inc. (PCRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Pacira BioSciences, Inc. carries a market cap of $1.00B, a P/E ratio of 68.39x, a P/B ratio of 1.49x, a P/S ratio of 1.34x, an enterprise value of $1.16B, and an EV/EBITDA multiple of 11.03x. On profitability, it posts a gross margin of 79.21%, an operating margin of 2.66%, a net margin of 1.96%, a Return on Equity (ROE) of 2.05%, a Return on Assets (ROA) of 1.05%, and a Return on Invested Capital (ROIC) of 1.74%. Per share, it reports EPS of $0.37, diluted EPS of $0.36, free cash flow per share of $4.55, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 5.71% year-over-year, net income growth of -111.48% year-over-year, and EPS growth of -113.23% year-over-year. On the balance sheet, it maintains a current ratio of 5.04x, a quick ratio of 3.69x, working capital of $493.20M, a debt-to-equity ratio of 0.85x, a debt ratio of 0.46, an interest coverage ratio of 1.28x, free cash flow of $179.51M (TTM), and net debt of $157.25M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.00B
- P/E TTM
- 68.39x
- EPS TTM
- $0.37
- P/B TTM
- 1.49x
- ROE TTM
- 2.05%
- ROA TTM
- 1.05%
- Debt To Equity
- 0.85x
- Free Cash Flow TTM
- $179.51M
- Net Revenue TTM Growth 1Y
- 5.71%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Pacira BioSciences, Inc. in?
Pacira BioSciences, Inc. (PCRX) operates in the Pharmaceutical Preparations industry.
What exchange does PCRX trade on?
Pacira BioSciences, Inc. (PCRX) trades on the Nasdaq.
Where is Pacira BioSciences, Inc. incorporated?
Pacira BioSciences, Inc. is incorporated in DE.
When was Pacira BioSciences, Inc. (PCRX)'s most recent SEC filing?
Pacira BioSciences, Inc. (PCRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is PCRX's market cap?
Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.00B as of 2026-06-30.
What is PCRX's P/E ratio?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month P/E ratio is 68.39x as of 2026-06-30.
What is PCRX's EPS (earnings per share)?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month EPS is $0.37 as of 2026-06-30.
What is PCRX's ROE (return on equity)?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month Return on Equity (ROE) is 2.05% as of 2026-06-30.
What is PCRX's ROA (return on assets)?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month Return on Assets (ROA) is 1.05% as of 2026-06-30.
What is PCRX's ROIC (return on invested capital)?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month Return on Invested Capital (ROIC) is 1.74% as of 2026-06-30.
What is PCRX's EV/EBITDA?
Pacira BioSciences, Inc. (PCRX)'s trailing twelve month EV/EBITDA is 11.03x as of 2026-06-30.